2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals
'Every day uninsured patients face barriers to accessing basic mental health services they need,' said Carol Richardson, Sustainability and Health Equity Lead, Teva U.S. 'This latest round of grant funding will enable clinics in more states to expand existing or develop innovative new behavioral health programs that meet the needs of their local patient populations'.
Over the first two years, Community Routes grantees demonstrated significant impact across their communities reaching more than 63,000 beneficiaries. Clinics conducted 24,617 patient screenings for depression, anxiety, and adverse childhood experiences, helping identify and address previously unmet mental health needs. The program extended beyond direct patient care, with grantees training more than 2,800 community members, staff, and volunteers in mental health promotion and well-being. Additionally, clinics organized 131 community events to expand access to mental health education and services, strengthening their role as trusted healthcare resources.
Building on these achievements, this funding cycle prioritizes the creation and expansion of innovative care delivery models that integrate behavioral health services into existing clinical operations, with particular emphasis on evidence-based screening tools and treatment protocols for depression and anxiety.
'Mental health is an essential component of overall well-being, yet too many individuals in underserved communities struggle to access the care they need,' shared Nicole Lamoureux, NAFC President & CEO. 'This program empowers clinics to bridge this gap by expanding behavioral health services and critical mental health support. By investing in these clinics, we are investing in the health and resilience of entire communities.'
The 2025 grant recipients include:
Alabama:
Mississippi:
Texas:
Selected programs emphasize sustainable integration of mental health services through:
'Expanding mental health services in resource-limited settings has been a key focus of prior Community Routes funding, and this latest round will allow providers to reach even more people with critical services,' said Katie Lewis, Regional Director of U.S. Programs for Direct Relief. 'These funds will allow clinics to build on successful approaches while exploring new strategies that fit the unique needs of the people and communities they serve.'
For a report on lessons learned from our Community Routes: Access to Mental Healthcare grantees, click here.
Community Routes: Access to Mental Health Care—a partnership between Teva, Direct Relief, and the National Association of Free and Charitable Clinics (NAFC)— is a unique access program that is helping to advance health equity and quality care for underserved populations across the U.S.
Teva is providing commonly used medicines that treat depression and anxiety to 400+ clinics in 10 states, as well as $4 million in grant funding to support innovative behavioral health services through local free and charitable clinics, tailored to meet the needs of their communities. To read more click here.
About Direct Relief
Direct Relief is a humanitarian aid organization, active in all 50 states and more than 80 countries, with a mission to improve the health and lives of people affected by poverty or emergencies. Direct Relief works with healthcare providers operating in resource-limited communities to help them care for their patients by providing essential medical supplies and equipment. Learn more at DirectRelief.org.
About National Association of Free and Charitable Clinics
National Association of Free and Charitable Clinics (NAFC) is the only nonprofit 501c (3) organization whose mission is solely focused on the issues and needs of the medically underserved throughout the nation and the more than 1,400 Free and Charitable Clinics that serve them. The NAFC has earned the Platinum Seal of Transparency from GuideStar and a 4-star rating from Charity Navigator. Founded in 2001 and headquartered near Washington, D.C., the NAFC is working to ensure that the medically underserved have access to affordable quality health care and strives to be a national voice promoting quality health care for all. For more information about the NAFC, please visit www.nafcclinics.org.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global pharmaceutical harnessing our generics expertise and stepping up innovation to continue the momentum behind the discovery, delivery, and expanded development of modern medicine. For over 120 years, Teva's commitment to bettering health has never wavered. Today, the company's global network of capabilities enables its ~37,000 employees across 57 markets to push the boundaries of scientific innovation and deliver quality medicines to help improve health outcomes of millions of patients every day. To learn more about how Teva is all in for better health, visit www.tevapharm.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
30-07-2025
- Business Wire
UZEDY ® Accelerates: 2025 Revenue Outlook Raised to $190–$200M (from ~$160M); Olanzapine LAI on Track for Submission in 2025
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell's (Paris:MEDCL) partner Teva Pharmaceuticals shared today the following information: About UZEDY ® 1-Month and 2-Month subcutaneous risperidone for schizophrenia Commercialized in the U.S. since May 2023 sales: $117 million Updated 2025 Revenue Outlook by Teva from ~$160 to $190 - $200 million Q2 2025 sales $54 million, 2.2x increase compared to Q2 2024 H1 2025 sales $93 million, 2.3x increase compared to H1 2024 Medincell receives mid- to high-single digit royalties on all sales and is eligible for $105 million of commercial milestones. About Olanzapine Long-Acting Injectable (TEV-749 / mdc-TJK) 1-Month subcutaneous olanzapine, the most prescribed antipsychotic for schizophrenia in the U.S. Pivotal Phase 3 completed in January 2025 with positive Phase 3 efficacy results 1 and no PDSS 2 Preparation for filing on track Full maintenance efficacy and safety data planned for presentation in Q3 2025 NDA 3 submission planned for Q4 2025 Following an NDA submission, the FDA takes approximately 2 months to determine acceptance for review, followed by an additional 8 months for a standard review, which may lead to approval. Medincell is eligible for $7 million in development milestone. Provided approval, Medincell will receive mid- to high-single digit royalties on all sales and will be eligible for $105 million of commercial milestones. Teva Q2 2025 earnings conference call today at 8:00am ET, webcast and replay: About Medincell Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable drugs in many therapeutic areas. Our innovative treatments aim to guarantee compliance with medical prescriptions, to improve the effectiveness and accessibility of medicines, and to reduce their environmental footprint. They combine active pharmaceutical ingredients with our proprietary BEPO ® technology which controls the delivery of a drug at a therapeutic level for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, entirely bioresorbable. The first treatment based on BEPO ® technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY ® (BEPO ® technology is licensed to Teva under the name SteadyTeq™). We collaborate with leading pharmaceutical companies and foundations to improve global health through new treatment options. Based in Montpellier, Medincell currently employs more than 140 people representing more than 25 different nationalities. UZEDY ® and SteadyTeq™ are trademarks of Teva Pharmaceuticals This press release contains forward-looking statements, including statements regarding Company's expectations for (i) the timing, progress and outcome of its clinical trials; (ii) the clinical benefits and competitive positioning of its product candidates; (iii) its ability to obtain regulatory approvals, commence commercial production and achieve market penetration and sales; (iv) its future product portfolio; (v) its future partnering arrangements; (vi) its future capital needs, capital expenditure plans and ability to obtain funding; and (vii) prospective financial matters regarding our business. Although the Company believes that its expectations are based on reasonable assumptions, any statements other than statements of historical facts that may be contained in this press release relating to future events are forward-looking statements and subject to change without notice, factors beyond the Company's control and the Company's financial capabilities. These statements may include, but are not limited to, any statement beginning with, followed by or including words or phrases such as "objective", "believe", "anticipate", 'expect', "foresee", "aim", "intend", "may", "anticipate", "estimate", "plan", "project", "will", "may", "probably", 'potential', "should", "could" and other words and phrases of the same meaning or used in negative form. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that may, if any, cause actual results, performance, or achievements to differ materially from those anticipated or expressed explicitly or implicitly by such forward-looking statements. A list and description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the Autorité des Marchés Financiers (the "AMF") pursuant to its regulatory obligations, including the Company's registration document, registered with the AMF on September 4, 2018, under number I. 18-062 (the "Registration Document"), as well as in the documents and reports to be published subsequently by the Company. In particular, readers' attention is drawn to the section entitled "Facteurs de Risques" on page 26 of the Registration Document. Any forward-looking statements made by or on behalf of the Company speak only as of the date they are made. Except as required by law, the Company does not undertake any obligation to publicly update these forward-looking statements or to update the reasons why actual results could differ materially from those anticipated by the forward-looking statements, including in the event that new information becomes available. The Company's update of one or more forward-looking statements does not imply that the Company will make any further updates to such forward-looking statements or other forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements. This press release is for information purposes only. The information contained herein does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for the Company's shares in any jurisdiction, in particular in France. Similarly, this press release does not constitute investment advice and should not be treated as such. It is not related to the investment objectives, financial situation, or specific needs of any recipient. It should not deprive the recipients of the opportunity to exercise their own judgment. All opinions expressed in this document are subject to change without notice. The distribution of this press release may be subject to legal restrictions in certain jurisdictions. 1 Presse Release, May 8, 2024: 2 Post-Injection Delirium/Sedation Syndrome (PDSS) is a rare but significant complication associated with existing long-acting injectable formulation of olanzapine. PDSS occurs when a portion of the injected medication unintentionally enters the bloodstream too quickly, causing sudden sedation, confusion, and potentially serious side effects such as respiratory issues. For healthcare providers and patients, PDSS remains a barrier to the widespread use of olanzapine LAI. The requirement for close post-injection monitoring limits the convenience and flexibility of this treatment option. Medincell's olanzapine LAI is designed to eliminate the risk of PDSS, potentially making it a safer and more accessible treatment option. Press release, Nov. 6, 2024: 3 NDA (New Drug Application): Formal request for approval to market a new pharmaceutical product, containing detailed data on its safety, efficacy, manufacturing, and labeling.
Associated Press
18-07-2025
- Associated Press
Direct Relief and FedEx Respond to Texas Flooding With Critical Medical Aid
When severe flooding struck Texas, homes were destroyed, roads were impassable, and access to medical care became critical. In response, Direct Relief quickly mobilized to support healthcare providers and first responders on the front lines of the crisis. Among the most urgent needs were emergency medical backpacks, packed with life-saving medications, medical tools, and essential supplies. These backpacks were requested to support ongoing search and rescue efforts and connect people facing flood effects with needed healthcare and services in the hardest-hit areas. However, with infrastructure severely disrupted, getting these supplies to where they were needed most was a challenge. That's where FedEx stepped in. Through their in-kind shipping support, FedEx ensured the timely delivery of six emergency medical backpacks to Texas. They also funded the backpacks, making it possible for Direct Relief to provide this vital assistance. These backpacks will supply healthcare workers and first responders with the necessary tools to care for flood survivors, helping them provide immediate relief in an already overwhelming situation. The collaboration between Direct Relief and FedEx highlights the importance of swift and reliable support in times of crisis, ensuring life-saving resources reach communities in need. This effort underscores how organizations can come together to make a tangible difference when disaster strikes. With FedEx's logistics expertise and Direct Relief's response efforts, communities in Texas are receiving the support they need to recover and rebuild. Click here to learn about FedEx Cares, our global community engagement program. Visit 3BL Media to see more multimedia and stories from FedEx
Yahoo
09-07-2025
- Yahoo
Teva Partners with Fosun Pharma to Advance Novel Cancer Immunotherapy TEV-56278
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the most promising stocks according to Wall Street analysts. On June 16, Teva Pharmaceutical announced a collaboration agreement with China-based Shanghai Fosun Pharmaceutical Group Co., Ltd. (better known as Fosun Pharma) to co-develop TEV-56278, which is an investigational anti-PD1-IL2 ATTENUKINE therapy. The partnership will accelerate clinical data generation for TEV-56278, which is currently in a Phase 1 study for various forms of cancer, such as melanoma. TEV-56278 is an internally developed Teva product and is an anti-PD-1 antibody-cytokine fusion protein that uses Teva's proprietary ATTENUKINE technology. A close-up shot of various types of medicines on a table, illustrating the specialty and generic products offered by the pharmaceutical company. Its novel mechanism of action is designed to selectively deliver interleukin-2 (IL-2) to PD-1-expressing T cells within the tumor microenvironment. Under the terms of the agreement, Fosun Pharma has been granted an exclusive license to develop, manufacture, and commercialize TEV-56278 in mainland China, the Hong Kong SAR, Macau SAR, Taiwan region, and select Southeast Asian countries. Teva Pharmaceutical Industries Limited (NYSE:TEVA) develops, manufactures, markets, and distributes generic & other medicines and biopharmaceutical products internationally. Fosun Pharma is a global healthcare company in pharmaceuticals, medical devices & diagnostics, and healthcare services. While we acknowledge the potential of TEVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
